 Mindset Pharma Inc CSE:MSET, OTCQB:MSSTF has announced an exclusive licensing agreement for Cybin Inc to acquire intellectual property rights for a subset of Mindsets preclinical compounds. Under the terms of the agreement, biopharmaceutical company Cybin will license intellectual property related to preclinical compounds within Mindsets Family 1 portfolio, excluding MSP-1014, Mindsets lead psychedelic drug candidate. 